Those who applied for
Congratulations to everyone who applied for the free trial.
※For those who missed the “COVID-19 treatment” opportunity, it’s okay. We are going out big once again.
※It finally starts. InnoTherapy(246960) follow-up stock hits the upper limit price on Tuesday※
Korea Electric Power is installing electric vehicle chargers at GS Caltex gas stations nationwide. On the 25th, Korea Electric Power signed an MOU with GS Caltex at the GS Tower in Seoul to cooperate on building electric vehicle charging infrastructure using gas stations and to develop a corporate customer electric vehicle charging service model!!
Interferon is a type of cytokine, a protein secreted by cells to transmit signals between immune cells or regulate immune responses, and is a glycoprotein that helps activate the immune system’s defense when viruses invade!!
“I applied and bought every day for 3 days, and I was amazed to see the upper limit price profit every day. It felt like a dream or a fantasy. It’s really amazing how this can happen. It’s been about 4 months since I paid the membership fee and received VIP service, and already 56 million KRW has accumulated in my account. I’m really grateful for making money every day. Ah! I’m actively recommending it to my acquaintances as well.” (VIP member Kim Cheol-gi, 56 years old)
▶▶ “September 29 upper limit price” offer ends today only..
Think of this as the last chance. If you miss this opportunity, you should quit.
It will explode exactly on “September 29”! Don’t miss it and regret it, buy even with just 1 million KRW!
▶▶ Only 30 people will be given. “Tuesday upper limit price”! ▶Receive now◀
※First-come, first-served 30 people limit! Both early and late rounds are over. The hero of the final injury time winning goal※
[Today’s stocks of interest]
#KoreaElectricPower #MPlus #BoseongPowerTech #NewInTech #NaraMND
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

